Lysine (K)-methyltransferase 2A (KMT2A) rearrangements, common in ALL and AML, enhance JAK-STAT signaling by downregulating IL-7R/IL-4R and suppressing KMT2A expression (199). The gene discussed is IL7R; the disease is acute lymphoblastic leukemia.